Northstrive Biosciences与Moa Life Plus签署许可协议修正案，共同开发靶向肌肉保留的双重肌肉生长抑制素资产，以联合GLP-1疗法

美股速递03-28

Northstrive Biosciences已与Moa Life Plus [Kosdaq: 142760]签署了一项许可协议修正案。此次合作的核心在于共同开发靶向肌肉保留的双重肌肉生长抑制素资产，旨在将其与GLP-1疗法结合使用。这一举措有望为相关治疗领域带来新的协同效应。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1132477234?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-28 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132477234","market":"us","top_or_hot":-1,"title":"Northstrive Biosciences与Moa Life Plus签署许可协议修正案，共同开发靶向肌肉保留的双重肌肉生长抑制素资产，以联合GLP-1疗法","media":"美股速递","content":"<p>Northstrive Biosciences已与Moa Life Plus [Kosdaq: 142760]签署了一项许可协议修正案。此次合作的核心在于共同开发靶向肌肉保留的双重肌肉生长抑制素资产，旨在将其与GLP-1疗法结合使用。这一举措有望为相关治疗领域带来新的协同效应。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Northstrive Biosciences与Moa Life Plus签署许可协议修正案，共同开发靶向肌肉保留的双重肌肉生长抑制素资产，以联合GLP-1疗法</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNorthstrive Biosciences与Moa Life Plus签署许可协议修正案，共同开发靶向肌肉保留的双重肌肉生长抑制素资产，以联合GLP-1疗法\n</h2>\n\n<h4 class=\"meta\">\n\n2026-03-28 04:06 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Northstrive Biosciences已与Moa Life Plus [Kosdaq: 142760]签署了一项许可协议修正案。此次合作的核心在于共同开发靶向肌肉保留的双重肌肉生长抑制素资产，旨在将其与GLP-1疗法结合使用。这一举措有望为相关治疗领域带来新的协同效应。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"个人用品","start_time":0,"source_url":"","article_id":"1132477234","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132477234","pubTimestamp":1774641974,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Northstrive Biosciences已与Moa Life Plus [Kosdaq: 142760]签署了一项许可协议修正案。此次合作的核心在于共同开发靶向肌肉保留的双重肌肉生长抑制素资产，旨在将其与GLP-1疗法结合使用。这一举措有望为相关治疗领域带来新的协同效应。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4183":"个人用品","ELAB":"PMGC Holdings"},"translate_title":"Northstrive Biosciences and Moa Life Plus sign license agreement amendments to jointly develop dual myostatin assets targeting muscle retention in combination with GLP-1 therapies","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELAB":1},"content_text":"Northstrive Biosciences已与Moa Life Plus [Kosdaq: 142760]签署了一项许可协议修正案。此次合作的核心在于共同开发靶向肌肉保留的双重肌肉生长抑制素资产，旨在将其与GLP-1疗法结合使用。这一举措有望为相关治疗领域带来新的协同效应。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132477234","isCrawlerRequest":true}